collegium pharmaceutical, inc. is a specialty pharmaceutical company developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. with a substantial number of patients suffering from chronic pain, collegium is committed to developing and commercializing a portfolio of products that address the growing problems associated with non-medical use, abuse and misuse of prescription products by leveraging the company’s proprietary deterx® technology platform. deterx technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have a narrow therapeutic index that would benefit from protection against misuse such as breaking, crushing, grinding, or dissolving the product. the deterx technology platform is covered by u.s. and international patents and patent applications. collegium’s lead product candidate, xtampza er™, is an abuse-deterrent, ex
Company profile
Ticker
COLL
Exchange
Website
CEO
Joseph Ciaffoni
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
COLLEGIUM PHARMACEUTICAL INC
SEC CIK
Corporate docs
Subsidiaries
Collegium Securities Corporation • Collegium NF, LLC • BioDelivery Sciences International, Inc. • Arius Pharmaceuticals, Inc. • Arius Two, Inc. ...
COLL stock data
Latest filings (excl ownership)
8-K
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
11 Apr 24
ARS
2023 FY
Annual report to shareholders
5 Apr 24
DEFA14A
Additional proxy soliciting materials
5 Apr 24
DEF 14A
Definitive proxy
5 Apr 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
22 Feb 24
8-K
Regulation FD Disclosure
3 Jan 24
8-K
Other Events
9 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Collegium Reports Third Quarter 2023 Financial Results
7 Nov 23
Transcripts
COLL
Earnings call transcript
2023 Q4
22 Feb 24
COLL
Earnings call transcript
2023 Q3
7 Nov 23
COLL
Earnings call transcript
2023 Q2
3 Aug 23
COLL
Earnings call transcript
2023 Q1
4 May 23
COLL
Earnings call transcript
2022 Q4
23 Feb 23
COLL
Earnings call transcript
2022 Q3
3 Nov 22
COLL
Earnings call transcript
2022 Q2
6 Aug 22
COLL
Earnings call transcript
2022 Q1
11 May 22
COLL
Earnings call transcript
2021 Q4
25 Feb 22
COLL
Earnings call transcript
2021 Q3
7 Nov 21
Latest ownership filings
4
Thomas B Smith
4 Mar 24
144
Notice of proposed sale of securities
29 Feb 24
4
Scott Dreyer
28 Feb 24
144
Notice of proposed sale of securities
26 Feb 24
4
Colleen Tupper
14 Feb 24
4
Scott Dreyer
14 Feb 24
4
Thomas B Smith
14 Feb 24
4
Shirley R. Kuhlmann
14 Feb 24
4
Joseph Ciaffoni
14 Feb 24
SC 13G/A
EVENTIDE ASSET MANAGEMENT, LLC
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 259.58 mm | 259.58 mm | 259.58 mm | 259.58 mm | 259.58 mm | 259.58 mm |
Cash burn (monthly) | 8.41 mm | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 58.35 mm | n/a | n/a | n/a | n/a | n/a |
Cash remaining | 201.23 mm | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | 23.9 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 176 |
Opened positions | 17 |
Closed positions | 23 |
Increased positions | 74 |
Reduced positions | 58 |
13F shares | Current |
---|---|
Total value | 852.75 bn |
Total shares | 39.78 mm |
Total puts | 41.70 k |
Total calls | 0.00 |
Total put/call ratio | Infinity |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 6.24 mm | $139.49 bn |
Rubric Capital Management | 3.18 mm | $70.96 bn |
Eventide Asset Managment | 2.63 mm | $58.81 bn |
Vanguard | 2.34 mm | $52.28 bn |
PFG Principal Financial Group Inc - Registered Shares | 1.58 mm | $35.30 bn |
Pacer Advisors | 1.29 mm | $28.86 bn |
STT State Street | 1.29 mm | $28.84 bn |
Renaissance Technologies | 1.17 mm | $26.21 bn |
IVZ Invesco | 1.16 mm | $25.92 bn |
Frazier Healthcare VI | 1.13 mm | $24.56 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Feb 24 | Thomas B Smith | Common Stock | Sell | Dispose S | No | No | 36.764 | 995 | 36.58 k | 63,409 |
26 Feb 24 | Dreyer Scott | Common Stock | Sell | Dispose S | No | Yes | 37.153 | 664 | 24.67 k | 138,918 |
26 Feb 24 | Dreyer Scott | Common Stock | Sell | Dispose S | No | Yes | 36.3754 | 9,336 | 339.60 k | 139,582 |
16 Jan 24 | Dreyer Scott | Common Stock | Sell | Dispose S | No | Yes | 32.2801 | 23,560 | 760.52 k | 111,322 |
21 Dec 23 | Ciaffoni Joseph | Common Stock | Sell | Dispose S | No | Yes | 30.3825 | 4,357 | 132.38 k | 275,000 |
21 Dec 23 | Ciaffoni Joseph | Common Stock | Option exercise | Acquire M | No | Yes | 21.34 | 4,357 | 92.98 k | 279,357 |
21 Dec 23 | Ciaffoni Joseph | Stock Option (Right to Purchase) Common Stock | Option exercise | Dispose M | No | Yes | 21.34 | 4,357 | 92.98 k | 16,875 |
20 Dec 23 | Ciaffoni Joseph | Common Stock | Sell | Dispose S | No | Yes | 30.4003 | 26,454 | 804.21 k | 275,000 |
20 Dec 23 | Ciaffoni Joseph | Common Stock | Option exercise | Acquire M | No | Yes | 21.34 | 26,454 | 564.53 k | 301,454 |
20 Dec 23 | Ciaffoni Joseph | Stock Option (Right to Purchase) Common Stock | Option exercise | Dispose M | No | Yes | 21.34 | 26,454 | 564.53 k | 21,232 |
News
Critical Insights From Collegium Pharmaceutical Analyst Ratings: What You Need To Know
11 Apr 24
Needham Reiterates Buy on Collegium Pharmaceutical, Maintains $40 Price Target
11 Apr 24
Truist Securities Maintains Buy on Collegium Pharmaceutical, Raises Price Target to $40
26 Feb 24
Where Collegium Pharmaceutical Stands With Analysts
23 Feb 24
Recap: Collegium Pharmaceutical Q4 Earnings
22 Feb 24